Myocardial infarction and viral triggers: what do we know by now?

被引:9
|
作者
Caldeira, Daniel [1 ,2 ,3 ,4 ]
Nogueira-Garcia, Beatriz [1 ,2 ]
机构
[1] Univ Lisbon, Ctr Cardiovasc Univ Lisboa CCUL, Fac Med, CAML, Lisbon, Portugal
[2] Hosp Univ Santa Maria CHULN, Cardiol Dept, Lisbon, Portugal
[3] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal
[4] Univ Lisbon, Fac Med, Ctr Estudos Med Baseada Evidencia CEMBE, Lisbon, Portugal
关键词
Acute coronary syndrome; Influenza vaccine; COVID-19; Troponin; Myocardial injury; HERPES-SIMPLEX-VIRUS; CARDIOVASCULAR-DISEASE; INFLUENZA VACCINATION; ACUTE INFECTION; RISK; CYTOMEGALOVIRUS; BURDEN; DEATH;
D O I
10.1093/eurheartjsupp/suac122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocardial infarction (MI) is an acute clinical manifestation ischaemic heart disease, which is the leading cause of death worldwide. Infections also have an important burden worldwide, with lower respiratory infections being the worldwide leading cause of death due to communicable diseases. The relationship of MI with viral respiratory infections (including influenza and SARS-CoV-2) as a trigger has been well documented with significant associations. These infections can lead to Type 1 MI, where inflammation and vascular dysfunction, as well as the increased prothrombotic environment lead to atherothrombosis. Type 2 MI may also occur due to an imbalance of oxygen/blood supply and myocardial demand (hypoxaemia, fever, and tachycardia). The data from randomized controlled trials showing a potential benefit of influenza vaccination in coronary artery disease patients should not be ignored. This can be considered a further argument for the association of viral infections (influenza in particular) and MI.
引用
收藏
页码:A12 / A16
页数:5
相关论文
共 50 条
  • [31] Healthy sexual life after a cardiac event: What do we know and what do we do now?
    Fridlund, Bengt
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2009, 8 (03) : 159 - 160
  • [32] NOW THAT WE KNOW HOW LOW THE RELIABILITY IS, WHAT SHALL WE DO
    SALZINGER, K
    BEHAVIORAL AND BRAIN SCIENCES, 1991, 14 (01) : 162 - 162
  • [33] What Do We Know about Asthma Triggers? A Review of the Literature
    Vernon, Margaret K.
    Wiklund, Ingela
    Bell, Jill A.
    Dale, Peter
    Chapman, Kenneth R.
    JOURNAL OF ASTHMA, 2012, 49 (10) : 991 - 998
  • [34] WHAT DO WE REALLY KNOW ABOUT SECONDARY PREVENTION AFTER MYOCARDIAL-INFARCTION
    WIELGOSZ, AT
    CANADIAN JOURNAL OF CARDIOLOGY, 1995, 11 : A31 - A32
  • [35] Long COVID: what do we know now and what are the challenges ahead?
    Pereira, Snehal M. Pinto
    Newlands, Fiona
    Anders, Jake
    Banerjee, Amitava
    Blandford, Ann
    Brown, Kate
    Beale, Sarah
    Bu, Feifei
    Fong, Wing Lam Erica
    Gilpin, Gina
    Hardelid, Pia
    Kovar, Jana
    Lim, Jason
    Park, Chloe
    Raveendran, Vishnuga
    Shah, Anoop D.
    Shao, Xin
    Wong, Andrew
    Stephenson, Terence
    Shafran, Roz
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2024, 117 (07) : 224 - 228
  • [36] Genetic platforms: Do we do what we know? or do we know what we do?
    Bernet, Laia
    Pla, Maria Jesus
    Janez, Noelia Martinez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (02): : 100 - 110
  • [37] COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?
    Ikizler, T. Alp
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (01) : 1 - 3
  • [38] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11
  • [39] Surgical myocardial revascularization in cardiogenic shock complicating acute myocardial infarction What do we currently know?
    Grieshaber, Philippe
    Boening, Andreas
    ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE, 2021, 35 (05): : 277 - 282
  • [40] We (Now) Know What We Are, But Not What We May Be
    Taner, Timucin
    Heimbach, Julie K.
    TRANSPLANTATION, 2019, 103 (10) : 1978 - 1979